Contents

Clinical Cancer Research
The Journal of Clinical and Translational Research
July 15, 2012 • Volume 18 • Number 14

Highlights of This Issue 3717

SPECIAL FEATURES

CCR Translations

3719 **Mind the Gap: Potential for Rebounds during Antiangiogenic Treatment Breaks**
John M.L. Ebos and Roberto Pili
See article p. 3961

CCR Perspectives in Drug Approval

3722 **Vandetanib for the Treatment of Symptomatic or Progressive Medullary Thyroid Cancer in Patients with Unresectable Locally Advanced or Metastatic Disease: U.S. Food and Drug Administration Drug Approval Summary**
Katherine Thornton, Geoffrey Kim, V. Ellen Maher, Somesh Chattopadhyay, Shenghui Tang, Young Jin Moon, Pengfei Song, Anshu Marathe, Suchitra Balakrishnan, Hao Zhu, Christine Garnett, Qi Liu, Brian Booth, Brenda Gehrke, Robert Dorsam, Leigh Verbois, Debasis Ghosh, Wendy Wilson, John Duan, Haripada Sarker, Sarah Pope Miksinski, Lisa Skarupa, Amna Ibrahim, Robert Justice, Anthony Murgo, and Richard Pazdur

Statistics in Clinical Cancer Research

3731 **Cure Models as a Useful Statistical Tool for Analyzing Survival**
Megan Othus, Bart Barlogie, Michael L. LeBlanc, and John J. Crowley

CCR Drug Updates

3737 **Crizotinib for *ALK*-Rearranged Non–Small Cell Lung Cancer: A New Targeted Therapy for a New Target**
Leena Gandhi and Pasi A. Jänne

Molecular Pathways

3743 **Molecular Pathways: Targeting P21-Activated Kinase 1 Signaling in Cancer—Opportunities, Challenges, and Limitations**
Jeyanthy Eswaran, Da-Qiang Li, Anil Shah, and Rakesh Kumar

Review

3750 **Combining Antiangiogenics to Overcome Resistance: Rationale and Clinical Experience**
Victor Moreno Garcia, Bristi Basu, L. Rhoda Molife, and Stan B. Kaye

HUMAN CANCER BIOLOGY

3762 **Tumor-Associated Macrophages in Pediatric Classical Hodgkin Lymphoma: Association with Epstein-Barr Virus, Lymphocyte Subsets, and Prognostic Impact**
Mário Henrique M. Barros, Rocio Hassan, and Gerald Niedobitek

3772 **Defective Epidermal Innate Immunity and Resultant Superficial Dermatophytosis in Adult T-cell Leukemia/Lymphoma**
Yu Sawada, Motonobu Nakamura, Rieko Kabashima-Kubo, Takatoshi Shimauchi, Miwa Kobayashi, and Yoshiki Tokura

3780 **FGFR4 Blockade Exerts Distinct Antitumorigenic Effects in Human Embryonal versus Alveolar Rhabdomyosarcoma**
Lisa E.S. Crose, Katherine T. Etheridge, Candy Chen, Brian Belyea, Lindsay J. Talbot, Rex C. Bentley, and Corinne M. Linardic

3791 **Integrative Genomic Analysis Implicates Gain of *PIK3CA* at 3q26 and *MYC* at 8q24 in Chronic Lymphocytic Leukemia**
Jennifer R. Brown, Megan Hanna, Bethany Tesar, Lillian Werner, Nathalie Pochet, John M. Asara, Yaoyu E. Wang, Paola dal Cin, Stacey M. Fernandes, Christina Thompson, Laura MacConaill, Catherine J. Wu, Yves Van de Peer, Mick Correll, Aviv Regev, Donna Neuberg, and Arnold S. Freedman

CANCER THERAPY: PRECLINICAL

3803 **Development and Characterization of a Novel CD19CherryLuciferase (CD19CL) Transgenic Mouse for the Preclinical Study of B-Cell Lymphomas**
Luigi Scotto, Marianna Kruithof-de Julio, Luca Paoluzzi, Matko Kalac, Enrica Marchi, Jairo Baquero Buitrago, Jennifer Amengual, Michael M. Shen, and Owen A. O'Connor

3812 **Development of a Human Monoclonal Antibody for Potential Therapy of CD27-Expressing Lymphoma and Leukemia**
Laura A. Vitale, Li-Zhen He, Lawrence J. Thomas, Jennifer Widger, Jeffrey Weidlick, Andrea Crocker, Thomas O'Neill, James Storey, Martin J. Glennie, Deanna M. Grote, Stephen M. Ansell, Henry Marsh, and Tibor Keler

3822 **Elevation of c-FLIP in Castrate-Resistant Prostate Cancer Antagonizes Therapeutic Response to Androgen Receptor–Targeted Therapy**
Clare McCourt, Pamela Maxwell, Roberta Mazzucchelli, Rodolfo Montironi, Marina Scarpelli, Manuel Salto-Tellez, Joe M. O'Sullivan, Daniel B. Longley, and David J.J. Waugh

3834 **Development of an Fc-Enhanced Anti–B7-H3 Monoclonal Antibody with Potent Antitumor Activity**
Deryk Loo, Ralph F. Alderson, Francine Z. Chen, Ling Huang, Wenjun Zhang, Sergey Gorlatov, Steve Burke, Valentina Ciccarone, Hua Li, Yinhua Yang, Tom Son, Yan Chen, Ann N. Easton, Jonathan C. Li, Jill R. Rillema, Monica Licea, Claudia Fieger, Tony W. Liang, Jennie P. Mather, Scott Koenig, Stanford J. Stewart, Syd Johnson, Ezio Bonvini, and Paul A. Moore

3846 **Antitumor Activity of Targeted and Cytotoxic Agents in Murine Subcutaneous Tumor Models Correlates with Clinical Response**
Harvey Wong, Edna F. Choo, Bruno Alicke, Xiao Ding, Hank La, Erin McNamara, Frank-Peter Theil, Jay Tibbitts, Lori S. Friedman, Cornelis E.C.A. Hop, and Stephen E. Gould

3856 **Anti-Myeloma Effects of the Novel Anthracycline Derivative INNO-206**
Eric Sanchez, Mingjie Li, Cathy Wang, Cydney M. Nichols, Jennifer Li, Haiming Chen, and James R. Berenson

3868 **Brachyury, a Driver of the Epithelial–Mesenchymal Transition, Is Overexpressed in Human Lung Tumors: An Opportunity for Novel Interventions against Lung Cancer**
Mario Roselli, Romaine I. Fernando, Fiorella Guadagni, Antonella Spila, Jhessica Alessandroni, Raffaele Palmirotta, Leopoldo Costarelli, Mary Litzinger, Duane Hamilton, Bruce Huang, Joanne Tucker, Kwong-Yok Tsang, Jeffrey Schlom, and Claudia Palena

3880 **Targeting Fibroblast Growth Factor Receptor Signaling Inhibits Prostate Cancer Progression**
Shu Feng, Longjiang Shao, Wendong Yu, Paul Gavine, and Michael Ittmann

3889 **Resistance to TRAIL Is Mediated by DARPP-32 in Gastric Cancer**
Abbes Belkhiri, Shoumin Zhu, Zheng Chen, Mohammed Soutto, and Wael El-Rifai

3901 **GDC-0941, a Novel Class I Selective PI3K Inhibitor, Enhances the Efficacy of Docetaxel in Human Breast Cancer Models by Increasing Cell Death *In Vitro* and *In Vivo***
Jeffrey J. Wallin, Jane Guan, Wei Wei Prior, Leslie B. Lee, Leanne Berry, Lisa D. Belmont, Hartmut Koeppen, Marcia Belvin, Lori S. Friedman, and Deepak Sampath

3912 **AT13148 Is a Novel, Oral Multi-AGC Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity**
Timothy A. Yap, Mike I. Walton, Kyla M. Grimshaw, Robert H. te Poele, Paul D. Eve, Melanie R. Valenti, Alexis K. de Haven Brandon, Vanessa Martins, Anna Zetterlund, Simon P. Heaton, Kathrin Heinzmann, Paul S. Jones, Ruth E. Feltell, Matthias Reule, Steven J. Woodhead, Thomas G. Davies, John F. Lyons, Florence I. Raynaud, Suzanne A. Eccles, Paul Workman, Neil T. Thompson, and Michelle D. Garrett

3924 **Vandetanib, an Inhibitor of VEGF Receptor-2 and EGF Receptor, Suppresses Tumor Development and Improves Prognosis of Liver Cancer in Mice**
Kinya Inoue, Takuji Torimura, Toru Nakamura, Hideki Iwamoto, Hiroshi Masuda, Mitsuhiko Abe, Osamu Hashimoto, Hironori Koga, Takato Ueno, Hirohisa Yano, and Michio Sata

IMAGING, DIAGNOSIS, PROGNOSIS

3934 **Pyrophosphorolysis-Activated Polymerization Detects Circulating Tumor DNA in Metastatic Uveal Melanoma**
Jordan Madic, Sophie Piperno-Neumann, Vincent Servois, Aurore Rampanou, Maud Milder, Bénédicte Trouiller, David Gentien, Stéphanie Saada, Franck Assayag, Aurélie Thuleau, Fariba Nemati, Didier Decaudin, François-Clément Bidard, Laurence Desjardins, Pascale Mariani, Olivier Lantz, and Marc-Henri Stern

3942 **A Replication Study and Genome-Wide Scan of Single-Nucleotide Polymorphisms Associated with Pancreatic Cancer Risk and Overall Survival**
Jason A. Willis, Sara H. Olson, Irene Orlow, Semanti Mukherjee, Robert R. McWilliams, Robert C. Kurtz, and Robert J. Klein

3952 **Multisite Validation Study to Determine Performance Characteristics of a 92-Gene Molecular Cancer Classifier**
Sarah E. Kerr, Catherine A. Schnabel, Peggy S. Sullivan, Yi Zhang, Veena Singh, Brittany Carey, Mark G. Erlander, W. Edward Highsmith, Sarah M. Dry, and Elena F. Brachtel

CANCER THERAPY: CLINICAL

3961 **Rapid Angiogenesis Onset after Discontinuation of Sunitinib Treatment of Renal Cell Carcinoma Patients**
Arjan W. Griffioen, Laurie A. Mans, Annemarie M.A. de Graaf, Patrycja Nowak-Sliwinska, Céline L.M.M. de Hoog, Trees A.M. de Jong, Florry A. Vyth-Dreese, Judy R. van Beijnum, Axel Bex, and Eric Jonasch
See commentary p. 3719

PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE

3972 **Predictive Value of *XRCC1* Gene Polymorphisms on Platinum-Based Chemotherapy in Advanced Non–Small Cell Lung Cancer Patients: A Systematic Review and Meta-analysis**
Junjie Wu, Jie Liu, Yuhao Zhou, Jun Ying, Houdong Zou, Shicheng Guo, Lei Wang, Naiqing Zhao, Jianjun Hu, Daru Lu, Li Jin, Qiang Li, and Jiu-Cun Wang

3982 **Genetic Polymorphisms in MicroRNA-Related Genes as Predictors of Clinical Outcomes in Colorectal Adenocarcinoma Patients**
Moubin Lin, Jian Gu, Cathy Eng, Lee M. Ellis, Michelle A. Hildebrandt, Jie Lin, Maosheng Huang, George A. Calin, Dingzhi Wang, Raymond N. DuBois, Ernest T. Hawk, and Xifeng Wu

3992 **Serum Insulin-Like Growth Factor-1 Levels Predict Outcomes of Patients with Advanced Hepatocellular Carcinoma Receiving Antiangiogenic Therapy**
Yu-Yun Shao, Chien-Chung Huang, Shiou-Der Lin, Chih-Hung Hsu, and Ann-Lii Cheng

CORRECTION

3998 **Correction: A Phase I Trial of Erlotinib and Concurrent Chemoradiotherapy for Stage III and IV (M0) Squamous Cell Carcinoma of the Head and Neck**

ABOUT THE COVER



The inhibition of androgen signaling is a major therapeutic strategy in prostate cancer; however, response is often transient, and patients ultimately relapse on therapy giving rise to a currently incurable condition known as castrate-resistant prostate cancer (CRPC). McCourt and colleagues show elevated expression of the androgen-regulated antiapoptotic protein c-FLIP in prostate cancer, which is further elevated in CRPC. Repression of c-FLIP induced apoptosis in non–castrate-resistant and CRPC cells and potentiated sensitivity to AR-targeted therapy, indicating that prostate cancer cells require c-FLIP to maintain viability. Consequently, targeting c-FLIP may represent a novel strategy to improve therapeutic response to the novel antiandrogen strategies under clinical development in CRPC. For details, see the article by McCourt and colleagues on page 3822 of this issue.

Clinical Cancer Research

18 (14)

Clin Cancer Res 2012;18:3717-3998.